Exelixis — CureCurrent

Published trials37

Recruiting shown7

Roles2

SourceClinicalTrials.gov

Clinical trials

37 shown

Study of XB010 in Subjects With Solid TumorsNCT06545331 · lead sponsor · 2024-08-06

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid TumorsNCT05932862 · lead sponsor · 2024-04-03

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsNCT05176483 · lead sponsor · 2021-12-14

Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)NCT07845786 · lead sponsor · 2026-12-15

NOT_YET_RECRUITING

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574 · lead sponsor · 2026-07-30

ENROLLING_BY_INVITATION

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)NCT04925284 · lead sponsor · 2021-06-07

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)NCT04726332 · lead sponsor · 2021-02-10

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · lead sponsor · 2020-10-19

ACTIVE_NOT_RECRUITING

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166 · lead sponsor · 2019-03-20

ACTIVE_NOT_RECRUITING

Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960 · lead sponsor · 2017-09-05

ACTIVE_NOT_RECRUITING

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058 · lead sponsor · 2014-02-01

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100NCT01605227 · lead sponsor · 2012-07-01

Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate CancerNCT01522443 · lead sponsor · 2012-03-01

Study of Cabozantinib (XL184) in Adults With Advanced MalignanciesNCT00940225 · lead sponsor · 2009-09-01

Safety Study of XL647 and XL147 Administered in Combination Daily in Adults With Solid TumorsNCT00704392 · lead sponsor · 2008-06-01

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)NCT00596648 · lead sponsor · 2008-02-12

Study of XL281 in Adults With Solid TumorsNCT00451880 · lead sponsor · 2007-02-01

Zanzalintinib in Men With Aggressive Variant Prostate CancerNCT07218666 · collaborator · 2026-08-19

XL092 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06568562 · collaborator · 2024-12-09

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate CancerNCT05613894 · collaborator · 2023-07-14

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityNCT01639508 · collaborator · 2012-07-01

Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate CancerNCT07623460 · collaborator · 2026-09-01

NOT_YET_RECRUITING

A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)NCT05859217 · collaborator · 2024-12-01

NOT_YET_RECRUITING

Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerNCT05502315 · collaborator · 2023-02-02

ACTIVE_NOT_RECRUITING

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyNCT04151563 · collaborator · 2021-04-15

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)NCT04631744 · collaborator · 2021-03-03

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)NCT04477512 · collaborator · 2021-02-19

Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyNCT04471428 · collaborator · 2020-10-01

Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate CancerNCT03964337 · collaborator · 2020-03-17

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerNCT03316586 · collaborator · 2017-11-30

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsNCT02795156 · collaborator · 2016-09-28

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain MetastasesNCT02132598 · collaborator · 2015-12-01

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain MetastasesNCT02260531 · collaborator · 2014-11-01

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerNCT01630590 · collaborator · 2014-01-08

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to BoneNCT01428219 · collaborator · 2012-02-01

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast CancerNCT01441947 · collaborator · 2011-10-01

A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung CancerNCT00927875 · collaborator · 2010-02-01

Sponsor roles

collaborator20

lead sponsor17

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.